S-adenosylmethionine

Phase 3Small molecule

IInstitute of Liver and Biliary Sciences, India

S-adenosylmethionine is one of 54 small molecule programs targeting Alcoholic Liver Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcoholic Liver DiseaseActive, not recruiting

Non-Alcoholic SteatohepatitisActive, not recruiting

Alcoholic Liver DiseasePhase 3

Active, not recruiting

Non-Alcoholic SteatohepatitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

96 competitors in Non-Alcoholic Steatohepatitis

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 3

4 2

Victoza

Novo Nordisk

Phase 3

2 3

Farxiga

AstraZeneca

Phase 2

1 4

Uloric

Takeda

Phase 2

1 5

Metadoxine

AAlcobra Ltd.

Phase 3

1 6

Dipeptidyl Peptidase 4 Inhibitor

Boehringer Ingelheim

Phase 3

1 7

Efruxifermin

Akero Therapeutics

Phase 3

1 8

Diosmin

TTanta University

Phase 3

1 9

Zetia

OOrganon and Co

Phase 2

2 10

Legalon

BBukwang Pharmaceutical

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Alcoholic Steatohepatitis2 trials

S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis

Completed·UUS Department of Veterans Affairs·Phase 3·NCT00108589

The Efficacy of S-adenosyl Methionine (SAMe) Versus Pentoxiphylline in Patients With Non-alcoholic Steatohepatitis With Fibrosis

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02231333·122 enrolled

Alcoholic Liver Disease1 trial

Effects of SAMe in Patients With Alcoholic Liver Disease

Completed·UUniversity of California, Davis·Phase 3·NCT00573313·94 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for S-adenosylmethionine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — S-adenosylmethionine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for S-adenosylmethionine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Liver and Biliary Sciences, India company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IInstitute of Liver and Biliary Sciences, India

S-adenosylmethionine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Alcoholic Steatohepatitis2 trials

Alcoholic Liver Disease1 trial

References

Drug Info

Quick Facts

Related News